The CIS-treated group showed a significant decrease in SOD (p ≤ 0.0001) and GSH (p ≤ 0.01) gene expression and showed a significant (p ≤ 0.0001) increase in CytP450 gene expression as compared to the EQ + CIS-treated group (Figure 4A–C). This evidence concerns the gene SOD1 and in situ carcinoma.